 |
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
LU25-109
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Pharmacological Role:
|
Lu 25-109 is a functionally selective partial M1 agonist
with M2/M3 antagonist properties.
|
Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a
muscarinic agonist, fails to improve cognition in
Alzheimer's disease. Lu25-109 Study Group. Neurology. 2000
Jan 25;54(2):421-6.
Abstract
Sanchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz
S, Matz J. In vivo muscarinic cholinergic mediated effects
of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro.
Psychopharmacology (Berl). 1998 Jun;137(3):233-40. Abstract
Muller D, Wiegmann H, Langer U, Moltzen-Lenz S, Nitsch RM.
Lu 25-109, a combined m1 agonist and m2 antagonist,
modulates regulated processing of the amyloid precursor
protein of Alzheimer's disease. J Neural Transm. 1998;105
(8-9):1029-43. Abstract
Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler
NR. A bridging study of LU 25-109 in patients with
probable Alzheimer's disease. Life Sci. 1998;62(3):195-202. Abstract
|
Home
